Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17597847 | 0.83 | VCP (0.33) | SOS1 | |
| SCHEMBL177743 | 0.79 | SOS1 (0.41) | SLC6A4SOS1 | |
| SCHEMBL276828 | 0.76 | EGFR (0.48) | SLC6A4EGFRKDR | |
| SCHEMBL29785358 | 0.76 | EGFR (0.48) | SLC6A4EGFRKDR | |
| SCHEMBL522748 | 0.74 | PPARG (0.41) | SLC6A4KCNH2 | |
| SCHEMBL423469 | 0.74 | ESR1 (0.41) | — | |
| SCHEMBL450533 | 0.74 | MRGPRX4 (0.39) | SLC6A4KDM1A | |
| Hydrochloric Acid SCHEMBL16634509 | 0.72 | ALDH1A1 (0.46) | SOS1 | |
| SCHEMBL30377217 | 0.72 | GPR3 (0.46) | SLC6A4EGFRKDRKIF11 | |
| SCHEMBL29556318 | 0.72 | SLC6A4 (0.47) | SLC6A4EGFRKDRKDM1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951993-B2 | Phosphorus containing compounds as protein kinase inhibitors | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2015-02-10 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2155722-B1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116050-A2 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20100121069-A1 | METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND | MSD K.K. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2170893-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-2155722-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009068652-A1 | 2, 6-DISUBSTITUTED PYRIDINES AND 2, 4-DISUBSTITUTED PYRIMIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| EP-2042478-A1 | METHOD FOR PRODUCING -DIARYL ELECTRON-WITHDRAWING GROUP SUBSTITUTED COMPOUND | Japan Science and Technology Agency (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008156739-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008153858-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | SLC6A4 4464/4885EGFR 184/4885KDR 558/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | SLC6A4 4193/4885EGFR 150/4885KDR 664/4885 |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | PPM1A, PPM1G, PPM1B | SLC6A4 3025/4885EGFR 709/4885KDR 1353/4885 |
| US-20100121069-A1 | METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND | BMP6, GPR6, ACSL6 | SLC6A4 1303/4885EGFR 2096/4885KDR 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.